AnaptysBioANAB
ANAB
About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees: 136
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 34
5.04% more ownership
Funds ownership: 111.35% [Q3] → 116.39% (+5.04%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
16% less funds holding
Funds holding: 160 [Q3] → 135 (-25) [Q4]
39% less call options, than puts
Call options by funds: $21M | Put options by funds: $34.3M
48% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 52
58% less capital invested
Capital invested by funds: $1.13B [Q3] → $469M (-$658M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
5%
upside
Avg. target
$39
84%
upside
High target
$51
142%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
JP Morgan Anupam Rama 17% 1-year accuracy 10 / 60 met price target | 100%upside $42 | Overweight Maintained | 5 Mar 2025 |
HC Wainwright & Co. Emily Bodnar 14% 1-year accuracy 23 / 160 met price target | 5%upside $22 | Neutral Reiterated | 4 Mar 2025 |
Wells Fargo Derek Archila 45% 1-year accuracy 14 / 31 met price target | 142%upside $51 | Overweight Maintained | 13 Feb 2025 |
Wedbush David Nierengarten 33% 1-year accuracy 39 / 119 met price target | 90%upside $40 | Outperform Maintained | 7 Feb 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
4 weeks ago
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
4 weeks ago
Anaptys Announces Stock Repurchase Plan
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share.
Negative
Zacks Investment Research
1 month ago
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data for rosnilimab in RA in Q2 2025 Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025 Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$420 million and reiterating cash runway through year-end 2027 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “Rosnilimab's positive Phase 2b data in rheumatoid arthritis has revealed impressive safety, tolerability and three-month efficacy data that was sustained and surpasses six-month data from competitor all-active, head-to-head trials.
Neutral
GlobeNewsWire
1 month ago
Anaptys Announces Participation in March Investor Conferences
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Mar. 4, 2025 at 1:10pm ET / 10:10am PT Leerink Partners 2025 Global Healthcare Conference, Miami, FL Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Mar. 11, 2025 at 10:40am ET / 7:40am PT Barclays 27 th Annual Global Healthcare Conference, Miami, FL Format – Presentation and one-on-one investor meetings Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
Positive
Zacks Investment Research
2 months ago
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?
Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
2 months ago
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Neutral
Investors Business Daily
2 months ago
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
Neutral
GlobeNewsWire
2 months ago
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28 Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs and reduction of CRP across all doses Rosnilimab was safe and well tolerated with similar adverse event rates vs.
Neutral
GlobeNewsWire
2 months ago
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.
Charts implemented using Lightweight Charts™